Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
il-15-stimulated allogeneic nk cells
- Development stage
- Unknown
- Lead developer
- Gregorio Marañón University General Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-15-stimulated allogeneic NK cells is an investigational adoptive cell therapy consisting of donor-derived natural killer (NK) cells (CD56+, CD3-) isolated from a haploidentical allogeneic donor. The production process involves a double immunomagnetic depletion and enrichment protocol to isolate the NK cells, followed by ex vivo stimulation with interleukin-15 (IL-15) for approximately 12 to 20 hours. This stimulation is intended to enhance the anti-leukemic activity, survival, and cytotoxicity of the NK cells. The therapy is primarily being evaluated for the treatment of high-risk acute myeloid leukemia (AML) in adult patients undergoing unmanipulated haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide. The mechanism leverages the graft-versus-leukemia (GvL) effect, where the activated NK cells target and eliminate residual leukemic cells during immune reconstitution.
- Other names
- IL-15-stimulated donor NK cellsIL15-stimulated donor NK cellsIL 15-stimulated donor NK cellsIL-15-activated haploidentical NK cellsIL15-activated haploidentical NK cellsIL 15-activated haploidentical NK cellsCD56+ CD3- NK cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on il-15-stimulated allogeneic nk cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on il-15-stimulated allogeneic nk cells.